RLFT.Y Stock Overview A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Relief Therapeutics Holding SA Competitors Price History & Performance
Summary of share price highs, lows and changes for Relief Therapeutics Holding Historical stock prices Current Share Price CHF 4.80 52 Week High CHF 7.71 52 Week Low CHF 1.05 Beta -14.7 1 Month Change -19.67% 3 Month Change 86.05% 1 Year Change 128.57% 3 Year Change -79.92% 5 Year Change n/a Change since IPO -88.00%
Recent News & Updates
Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial Dec 16
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Nov 11 Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million. Nov 05
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents Oct 25
Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Oct 08
Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria Oct 04 See more updates
Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial Dec 16
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Nov 11 Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million. Nov 05
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents Oct 25
Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Oct 08
Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria Oct 04
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024 Sep 18
Relief Therapeutics Holding SA Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Sep 02 Relief Therapeutics Holding SA to Report First Half, 2024 Results on Aug 30, 2024 Jun 28
Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors
Relief Therapeutics Holding SA, Annual General Meeting, Jun 27, 2024 May 31 Relief Therapeutics Announces Executive Changes Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor Feb 28
Relief Therapeutics Holding Sa Announces CEO Changes Nov 22 Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding Jun 17
Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023 May 26
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa Feb 14
RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom Jan 17
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders Dec 28
Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc. Dec 22
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements Dec 20 Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer
Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) Nov 07
RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer Oct 14
Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE Oct 11
Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago Sep 22 Relief Therapeutics Holding AG has filed an IPO. Aug 24
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation Aug 23
Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022 Aug 17
RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease Aug 13
Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application Aug 06 Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine Jul 18
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001 Jun 22
Relief Therapeutics Expands U.S. Commercial Team May 24
Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference May 08
Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022 May 06
Relief Therapeutics Holding AG Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing Apr 26
Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting Apr 12
Relief Therapeutics Holding SA Files Trademark Application for RLF-100 with the U.S. Patent and Trademark Office Feb 08
Relief Therapeutics Holding AG Approves Election of Michelle Lock as New Member of the Board of Directors Jan 31
NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics Jan 13
Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-Induced Pneumonitis Dec 28
Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil Dec 16 Shareholder Returns RLFT.Y US Biotechs US Market 7D 11.1% -3.8% -2.7% 1Y 128.6% -2.6% 23.4%
See full shareholder returns
Return vs Industry: RLFT.Y exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: RLFT.Y exceeded the US Market which returned 23.4% over the past year.
Price Volatility Is RLFT.Y's price volatile compared to industry and market? RLFT.Y volatility RLFT.Y Average Weekly Movement 27.5% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: RLFT.Y's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RLFT.Y's volatility change over the past year.
About the Company Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
Show more Relief Therapeutics Holding SA Fundamentals Summary How do Relief Therapeutics Holding's earnings and revenue compare to its market cap? RLFT.Y fundamental statistics Market cap US$61.09m Earnings (TTM ) -US$51.78m Revenue (TTM ) US$9.63m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RLFT.Y income statement (TTM ) Revenue CHF 8.60m Cost of Revenue CHF 2.70m Gross Profit CHF 5.90m Other Expenses CHF 52.13m Earnings -CHF 46.24m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -3.69 Gross Margin 68.56% Net Profit Margin -537.79% Debt/Equity Ratio 0.02%
How did RLFT.Y perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 10:17 End of Day Share Price 2024/12/19 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Relief Therapeutics Holding SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alexandre Müller Research Dynamics Bob Pooler ValuationLAB AG
Show 0 more analysts 